The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Toward a Molecular Classification of Melanoma
Abstract
The incidence of melanoma is increasing at one of the highest rates of any form of cancer in the United States, with the current lifetime risk being one in 68. At present, there are limited systemic therapies to treat advanced stages of melanoma, and the key to improved survival remains early detection. Recent discoveries have allowed for a clearer picture of the molecular events leading to melanoma development and progression. Since identifying prevalent activating mutations of the BRAF kinase in melanomas, there has been a flood of additional molecular studies to further clarify the role of this pathway and others in melanomagenesis. In particular, recent genetic studies have demonstrated specific genotype-phenotype correlations that provide the first major insights into the molecular subclassification of melanoma and the heterogeneous nature of this malignancy. In this article, we review the most up-to-date molecular discoveries in melanoma biology and provide a framework for understanding their significance in melanoma development and progression. We also provide details on the development of novel therapies based on these recent molecular discoveries and insight into current and planned clinical trials. It is expected that these latest studies in melanoma will help define the critical molecular events involved in disease onset and progression and allow us to move rapidly toward a true molecular classification. We eagerly anticipate rationally designed melanoma therapies based on such a classification scheme and the associated improvements in patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Balch, C. M., Soong, S.-J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., Urist, M., McMasters, K. M., Ross, M. I., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3622 · Cited by 2,388
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
The histogenesis and biologic behavior of primary human malignant melanomas of the skin.
Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Somatic Activation of KIT in Distinct Subtypes of Melanoma
Curtin, J. A., Busam, K., Pinkel, D., & Bastian, B. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2984 · Cited by 1,616
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
The complexity of p53 modulation: emerging patterns from divergent signals
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,314
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227
The Rb/E2F pathway: expanding roles and emerging paradigms
Harbour, J. W., & Dean, D. C. (2000) · Genes & Development · doi:10.1101/gad.813200 · Cited by 1,153
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
MAP kinase kinase kinase, MAP kinase kinase and MAP kinase
Marshall, C. J. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90095-7 · Cited by 999
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818
Targeting the Cell Cycle: A New Approach to Cancer Therapy
Schwartz, G. K., & Shah, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5594 · Cited by 817
Melanocytes and the Microphthalmia Transcription Factor Network
Steingrímsson, E., Copeland, N. G., & Jenkins, N. A. (2004) · Annual Review of Genetics · doi:10.1146/annurev.genet.38.072902.092717 · Cited by 771
Role of the p16 tumor suppressor gene in cancer.
Liggett, W. H., & Sidransky, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1197 · Cited by 746
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
Tumor suppression by Ink4a-Arf: progress and puzzles.
Lowe, S. W., & Sherr, C. J. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00013-8 · Cited by 699
Determinants of BRAF Mutations in Primary Melanomas
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg123 · Cited by 664
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603291 · Cited by 644
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
Lux, M. L., Rubin, B. P., Biase, T. L., Chen, C.-J., Maclure, T., Demetri, G., Xiao, S., Singer, S., Fletcher, C. D. M., & Fletcher, J. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64946-2 · Cited by 642
Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase
Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Kraus, M. L., Scheibe, D. N., Snell, G. P., Zou, H., Sang, B.-C., & Wilson, K. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403319200 · Cited by 635
MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes
Hemesath, T. J., Price, E. R., Takemoto, C., Badalian, T., & Fisher, D. E. (1998) · Nature · doi:10.1038/34681 · Cited by 630
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., Kester, M., Sandirasegarane, L., & Robertson, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1399 · Cited by 594
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A. (2001) · Nature · doi:10.1038/35092584 · Cited by 568
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
Maloney, A., & Workman, P. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.1.3 · Cited by 531
Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus.
Rapp, U. R., Goldsborough, M. D., Mark, G. E., Bonner, T. I., Groffen, J., Reynolds, F. H., & Stephenson, J. R. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4218 · Cited by 483
PTEN signaling pathways in melanoma
Wu, H., Goel, V., & Haluska, F. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206451 · Cited by 480
Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage
Goding, C. R. (2000) · Genes & Development · doi:10.1101/gad.14.14.1712 · Cited by 471
Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467
Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
Ma, Y., Zeng, S., Metcalfe, D. D., Akin, C., Dimitrijevic, S., Butterfield, J. H., McMahon, G., & Longley, B. J. (2002) · Blood · doi:10.1182/blood.v99.5.1741 · Cited by 449
Melanocytic Nevi, Solar Keratoses, and Divergent Pathways to Cutaneous Melanoma
Whiteman, D. C., Watt, P., Purdie, D. M., Hughes, M. C., Hayward, N. K., & Green, A. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.11.806 · Cited by 449
The classification of malignant melanoma and its histologic reporting
McGovern, V. J., Mihm, M. C., Bailly, C., Booth, J. C., Clark, W. H., Cochran, A. J., Hardy, E. G., Hicks, J. D., Levene, A., Lewis, M. G., et al. (1973) · Cancer · doi:10.1002/1097-0142(197312)32:6<1446::aid-cncr2820320623>3.0.co;2-8 · Cited by 443
Targeting the ERK signaling pathway in cancer therapy
Kohno, M., & Pouyssegur, J. (2006) · Annals of Medicine · doi:10.1080/07853890600551037 · Cited by 416
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 408
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. (2003) · PubMed · Cited by 407
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo
Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner, J. W., & DePinho, R. A. (1997) · Genes & Development · doi:10.1101/gad.11.21.2822 · Cited by 402
Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma
Goel, V. K., Lazar, A. J. F., Warneke, C. L., Redston, M. S., & Haluska, F. G. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700026 · Cited by 392
Soufir, N. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.2.209 · Cited by 386
Widlund, H. R., & Fisher, D. E. (2003) · Oncogene · doi:10.1038/sj.onc.1206443 · Cited by 371
Escudier, B., Szczylik, C., Eisen, T., Stadler, W. M., Schwartz, B., Shan, M., & Bukowski, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba4510 · Cited by 348
MC1R Germline Variants Confer Risk for BRAF -Mutant Melanoma
Landi, M. T., Bauer, J., Pfeiffer, R. M., Elder, D. E., Hulley, B., Minghetti, P., Calista, D., Kanetsky, P. A., Pinkel, D., & Bastian, B. C. (2006) · Science · doi:10.1126/science.1127515 · Cited by 346
V599EB-RAF is an Oncogene in Melanocytes
Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C. J., & Marais, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3433 · Cited by 344
(1999) · PubMed · Cited by 338
Genetics of melanoma predisposition
Hayward, N. K. (2003) · Oncogene · doi:10.1038/sj.onc.1206445 · Cited by 321
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
Chen, Y.-N. P., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., & Kaelin, W. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4325 · Cited by 314
Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 313
Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series
Bardia, A., Loprinzi, C. L., & Goetz, M. P. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1143 · Cited by 312
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds
Gruis, N. A., van der Velden, P. A., Sandkuijl, L. A., Prins, D. E., Weaver-Feldhaus, J., Kamb, A., Bergman, W., & Frants, R. R. (1995) · Nature Genetics · doi:10.1038/ng0795-351 · Cited by 310
Jin, S., & Levine, A. J. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.23.4139 · Cited by 307
Mechanisms of drug inhibition of signalling molecules
Sebolt-Leopold, J. S., & English, J. M. (2006) · Nature · doi:10.1038/nature04874 · Cited by 304
Raf: A Strategic Target for Therapeutic Development Against Cancer
Beeram, M., Patnaik, A., & Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.036 · Cited by 298
Houben, R., Becker, J. C., Kappel, A., Terheyden, P. A. M., Bröcker, E., Goetz, R., & Rapp, U. R. (2004) · Journal of Carcinogenesis · doi:10.1186/1477-3163-3-6 · Cited by 294
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2319 · Cited by 291
Oncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 287
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
van 't Veer, L. J., Burgering, B. M., Versteeg, R., Boot, A. J., Ruiter, D. J., Osanto, S., Schrier, P. I., & Bos, J. L. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.7.3114 · Cited by 283
A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family
Randerson-Moor, J. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.1.55 · Cited by 281
Epigenetic Silencing of the PTEN Gene in Melanoma
Mirmohammadsadegh, A., Marini, A., Nambiar, S., Hassan, M., Tannapfel, A., Ruzicka, T., & Hengge, U. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0384 · Cited by 279
Oncogenic Ras and its role in tumor cell invasion and metastasis
Campbell, P. M., & Der, C. J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.015 · Cited by 275
Wyman, K., Atkins, M. B., Prieto, V., Eton, O., McDermott, D. F., Hubbard, F., Byrnes, C., Sanders, K., & Sosman, J. A. (2006) · Cancer · doi:10.1002/cncr.21834 · Cited by 274
Meier, F. (2005) · Frontiers in Bioscience · doi:10.2741/1755 · Cited by 267
The INK4a/ARF locus and melanoma
Sharpless, N. E., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206461 · Cited by 261
Frost, M. J., Ferrao, P. T., Hughes, T. P., & Ashman, L. K. (2002) · PubMed · Cited by 249
Proteasome Inhibition: a New Strategy in Cancer Treatment
Adams, J., Palombella, V. J., & Elliott, P. J. (2000) · Investigational New Drugs · doi:10.1023/a:1006321828515 · Cited by 248
da Rocha Dias, S., Friedlos, F., Light, Y., Springer, C., Workman, P., & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2632 · Cited by 246
Raf kinase as a target for anticancer therapeutics
Sridhar, S. S., Hedley, D., & Siu, L. L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0297 · Cited by 245
Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines
Tsao, H., Zhang, X., Benoit, E., & Haluska, F. G. (1998) · Oncogene · doi:10.1038/sj.onc.1201881 · Cited by 243
Loss of PTEN promotes tumor development in malignant melanoma.
Stahl, J. M., Cheung, M., Sharma, A. K., Trivedi, N. R., Shanmugam, S., & Robertson, G. P. (2003) · PubMed · Cited by 241
Willmore-Payne, C., Holden, J. A., Tripp, S., & Layfield, L. J. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.03.015 · Cited by 230
CCI‐779 in metastatic melanoma: A Phase II trial of the California Cancer Consortium
Margolin, K., Longmate, J., Baratta, T., Synold, T., Christensen, S., Weber, J., Gajewski, T., Quirt, I., & Doroshow, J. H. (2005) · Cancer · doi:10.1002/cncr.21265 · Cited by 227
Isozaki, K., Terris, B., Belghiti, J., Schiffmann, S., Hirota, S., & Vanderwinden, J.-M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64795-5 · Cited by 223
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
Parulekar, W. R., & Eisenhauer, E. A. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh182 · Cited by 223
Mutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions
Yazdi, A. S., Palmedo, G., Flaig, M. J., Puchta, U., Reckwerth, A., Rütten, A., Mentzel, T., Hügel, H., Hantschke, M., Schmid-Wendtner, M.-H., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12559.x · Cited by 221
RAS Mutations in Human Melanoma: A Marker of Malignant Progression
Ball, N. J., Yohn, J. J., Morelli, J. G., Norris, D. A., Golitz, L. E., & Hoeffler, J. P. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12371783 · Cited by 221
Albino, A. P., Nanus, D. M., Mentle, I. R., Cordon‐Cardo, C., McNutt, N. S., Bressler, J., & Andreeff, M. (1989) · PubMed · Cited by 212
Straume, O., Sviland, L., & Akslen, L. A. (2000) · PubMed · Cited by 209
Lennartsson, J., Blume-Jensen, P., Hermanson, M., Pontén, E., Carlberg, M., & Rönnstrand, L. (1999) · Oncogene · doi:10.1038/sj.onc.1202929 · Cited by 208
Oncogenic MITF dysregulation in clear cell sarcoma: Defining the MiT family of human cancers
Davis, I. J., Kim, J. J., Ozsolak, F., Widlund, H. R., Rozenblatt-Rosen, O., Granter, S. R., Du, J., Fletcher, J. A., Denny, C. T., Lessnick, S. L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.021 · Cited by 202
CDKN2A Variants in a Population-Based Sample of Queensland Families With Melanoma
Aitken, J., Welch, J., Duffy, D., Milligan, A., Green, A., Martin, N., & Hayward, N. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.446 · Cited by 200
Measuring response in a post-RECIST world: from black and white to shades of grey
Michaelis, L. C., & Ratain, M. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1883 · Cited by 192
Functional and therapeutic significance of Akt deregulation in malignant melanoma
Robertson, G. P. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1577-9 · Cited by 189
Sensi, M., Nicolini, G., Petti, C., Bersani, I., Lozupone, F., Molla, A., Vegetti, C., Nonaka, D., Mortarini, R., Parmiani, G., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209379 · Cited by 183
Cutaneous melanoma: Prognosis and treatment results worldwide
Balch, C. M. (1992) · Seminars in Surgical Oncology · doi:10.1002/ssu.2980080611 · Cited by 182
Granville, C. A., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1654 · Cited by 181
A melanoma-associated germline mutation in exon 1β inactivates p14ARF
Rizos, H., Puig, S., Badenas, C., Malvehy, J., Darmanian, A. P., Jiménez, L., Milà, M., & Kefford, R. F. (2001) · Oncogene · doi:10.1038/sj.onc.1204728 · Cited by 171
Mutation and expression of the p53 gene in human malignant melanoma
Albino, A. P., Vidal, M. J., McNutt, N. S., Shea, C. R., Prieto, V. G., Nanus, D. M., Palmer, J. M., & Hayward, N. K. (1994) · Melanoma Research · doi:10.1097/00008390-199402000-00006 · Cited by 166
Bahuau, M., Vidaud, D., Jenkins, R. B., Bièche, I., Kimmel, D. W., Assouline, B., Smith, J. S., Alderete, B. E., Cayuela, J., Harpey, J. P., et al. (1998) · PubMed · Cited by 163
Funasaka, Y., Boulton, T., Cobb, M., Yarden, Y., Fan, B., Lyman, S. D., Williams, D. E., Anderson, D. M., Zakut, R., & Mishima, Y. (1992) · Molecular Biology of the Cell · doi:10.1091/mbc.3.2.197 · Cited by 161
A genome-based strategy uncovers frequent BRAF mutations in melanoma
Pollock, P. M., & Meltzer, P. S. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00089-2 · Cited by 160
Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma
Flaherty, K. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2505 · Cited by 159
The ins and outs of RB: coupling gene expression to the cell cycle clock
Sherr, C. J. (1994) · Trends in Cell Biology · doi:10.1016/0962-8924(94)90033-7 · Cited by 140
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
Flores, J. F., Walker, G. J., Glendening, J. M., Haluska, F. G., Castresana, J. S., Rubio, M., Pastorfide, G. C., Boyer, L. A., Kao, W. H., Bulyk, M. L., et al. (1996) · PubMed · Cited by 137
A phase II study of bortezomib in the treatment of metastatic malignant melanoma
Markovic, S. N., Geyer, S. M., Dawkins, F. W., Sharfman, W., Albertini, M. R., Maples, W. J., Fracasso, P. M., Fitch, T. R., LoRusso, P. M., Adjei, A. A., et al. (2005) · Cancer · doi:10.1002/cncr.21108 · Cited by 135
Exon 15 BRAF Mutations Are Uncommon in Melanomas Arising in Nonsun-Exposed Sites
Cohen, Y., Rosenbaum, E., Begum, S., Goldenberg, D., Esche, C., Lavie, O., Sidransky, D., & Westra, W. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0562 · Cited by 134
Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model
Kannan, K., Sharpless, N. E., Xu, J., O’Hagan, R. C., Bosenberg, M., & Chin, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336397100 · Cited by 120
Polsky, D., Bastian, B. C., Hazan, C., Melzer, K., Pack, J., Houghton, A., BUSAM, K. J., Cordon‐Cardo, C., & Osman, I. (2001) · PubMed · Cited by 120
Targeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma
Panka, D. J., Atkins, M. B., & Mier, J. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2539 · Cited by 120
Mutations of PIK3CA are rare in cutaneous melanoma
Omholt, K., Kröckel, D., Ringborg, U. K., & Hansson, J. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000200488.77970.e3 · Cited by 114
Absence of p53 Gene Mutations in Cutaneous Melanoma
Lübbe, J., Reichel, M., Burg, G., & Kleihues, P. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12381544 · Cited by 113
Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma
Ernst, D. S., Eisenhauer, E. A., Wainman, N., Davis, M., Lohmann, R. C., Baetz, T. D., Bélanger, K., & Smylie, M. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1157-4 · Cited by 108
Petti, C., Molla, A., Vegetti, C., Ferrone, S., Anichini, A., & Sensi, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4671 · Cited by 103
Expression of Activated Akt and PTEN in Malignant Melanomas
Slipicevic, A., Holm, R., Nguyen, M. T. P., Bøhler, P. J., Davidson, B., & Flørenes, V. A. (2005) · American Journal of Clinical Pathology · doi:10.1309/yt58wwmta6yr1prv · Cited by 102
Epigenetic Inactivation of Tumor Suppressor Genes in Serum of Patients with Cutaneous Melanoma
Marini, A., Mirmohammadsadegh, A., Nambiar, S., Gustrau, A., Ruzicka, T., & Hengge, U. R. (2005) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700073 · Cited by 100
BRAF and c-kit gene copy number in mutation-positive malignant melanoma
Willmore‐Payne, C., Holden, J. A., Hirschowitz, S. L., & Layfield, L. J. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.01.003 · Cited by 100
Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma
Pho, L. N., Grossman, D., & Leachman, S. A. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000208791.22442.09 · Cited by 99
Carpenter, J. T., Roche, H. H., Campone, M., Colomer, R., Jagiełło-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J. P., & Baselga, J. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.564 · Cited by 99
Spatz, A., Giglia‐Mari, G., Benhamou, S., & Sarasin, A. R. (2001) · PubMed · Cited by 96
Tumour suppressor retinoblastoma protein Rb: A transcriptional regulator
Zhu, L. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.009 · Cited by 91
Expression of the Tumor Suppressor Gene Product p16INK4 in Benign and Malignant Melanocytic Lesions
Keller‐Melchior, R., Schmidt, R. A., & Piepkorn, M. W. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00211.x · Cited by 90
Burdette-Radoux, S., Tozer, R. G., Lohmann, R. C., Quirt, I. C., Ernst, D. S., Walsh, W., Wainman, N., Colevas, A. D., & Eisenhauer, E. A. (2004) · Investigational New Drugs · doi:10.1023/b:drug.0000026258.02846.1c · Cited by 88
CDKN2A (p16INK4A) somatic and germline mutations
Smith‐Sørensen, B., & Hovig, E. J. (1996) · Human Mutation · doi:10.1002/(sici)1098-1004(1996)7:4<294::aid-humu2>3.0.co;2-9 · Cited by 87
Low Prevalence of Germline CDKN2A and CDK4 Mutations in Patients With Early-Onset Melanoma
Tsao, H., Zhang, X., Kwitkiwski, K., Finkelstein, D. M., Sober, A. J., & Haluska, F. G. (2000) · Archives of Dermatology · doi:10.1001/archderm.136.9.1118 · Cited by 87
Powell, M. B., Hyman, P., Bell, O. D., Balmain, A., Brown, K., Alberts, D., & Bowden, G. T. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940120205 · Cited by 84
HDM2 Protein Overexpression and Prognosis in Primary Malignant Melanoma
Polsky, D., Melzer, K., Hazan, C., Panageas, K. S., Busam, K., Drobnjak, M., Kamino, H., Spira, J. G., Kopf, A. W., Houghton, A., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.23.1803 · Cited by 83
Eisen, T. G., Bukowski, R. M., Staehler, M. D., Szczylik, C. A., Oudard, S. M., Stadler, W. M., Schwartz, B. E., Simantov, R., Shan, M., & Escudier, B. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4524 · Cited by 74
A mutation hotspot at the p14ARF splice site
Harland, M., Taylor, C., Chambers, P. A., Kukalizch, K., Randerson‐Moor, J. A., Gruis, N. A., de Snoo, F. A., ter Huurne, J., Goldstein, A. M., Tucker, M. A., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208678 · Cited by 73
Lang, J., & MacKie, R. M. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23833.x · Cited by 71
Grichnik, J. M. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700164 · Cited by 66
Rulyak, S. J., Brentnall, T. A., Lynch, H. T., & Austin, M. A. (2003) · Cancer · doi:10.1002/cncr.11562 · Cited by 65
Mutation testing in melanoma families: INK4A, CDK4 and INK4D
Newton‐Bishop, J., Harland, M., Bennett, D. C., Bataille, V. A., Goldstein, A. M., Tucker, M. A., Ponder, B. A. J., Cuzick, J. M., Selby, P., & Bishop, D. T. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690354 · Cited by 61
p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma
Fujimoto, A., Morita, R., Hatta, N., Takehara, K., & Takata, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202803 · Cited by 61
Population-Based Prevalence of CDKN2A Mutations in Utah Melanoma Families
Eliason, M. J., Larson, A. A., Florell, S. R., Zone, J. J., Cannon‐Albright, L., Samlowski, W. E., & Leachman, S. A. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700094 · Cited by 60
Koyanagi, K., O'Day, S. J., Gonzalez, R. C., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1847 · Cited by 57
van Elsas, A., Zerp, S. F., van der Flier, S., Krüse-Wolters, M., Vacca, A., Ruiter, D. J., & Schrier, P. I. (1995) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-78771-3_5 · Cited by 55
Rb/E2F: A two-edged sword in the melanocytic system
Halaban, R. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1582-z · Cited by 54
Sarkar-Agrawal, P., Vergilis, I., Sharpless, N. E., DePinho, R. A., & Runger, T. M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh307 · Cited by 48
Treatment of patients with metastatic melanoma with bryostatin-1 - phase II study
González, R., Ebbinghaus, S., Henthorn, T. K., Miller, D. M., & Kraft, A. S. (1999) · Melanoma Research · doi:10.1097/00008390-199912000-00010 · Cited by 45
Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type
Akslen, L. A., Monstad, S. E., Larsen, B., Straume, O., & Øgreid, D. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980220)79:1<91::aid-ijc17>3.0.co;2-k · Cited by 45
Phase II evaluation of bryostatin-1 in metastatic melanoma
Bedikian, A. Y., Plager, C., Stewart, J. R., O'Brian, C. A., Herdman, S., Ross, M., Papadopoulos, N., Eton, O. E., Ellerhorst, J. A., & Smith, T. (2001) · Melanoma Research · doi:10.1097/00008390-200104000-00014 · Cited by 40
Jankú, F., Novotný, J. P., Julis, I., Julišová, I., Pecen, L., Tomancová, V., Kocmanova, G., Krásná, L., Krajsová, I., Štork, J., et al. (2005) · Melanoma Research · doi:10.1097/00008390-200508000-00004 · Cited by 40
Potti, A., Moazzam, N., Langness, E., Sholes, K., Tendulkar, K. K., Koch, M., & Kargas, S. A. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0509-8 · Cited by 40
Genetics of familial and sporadic melanoma: Clinical dermatology • Review article
Bataille, V. A. (2000) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2000.00689.x · Cited by 36
Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma
Rao, R. D., Windschitl, H. E., Allred, J. B., Lowe, V. J., Maples, W. J., Gornet, M., Suman, V. J., Creagan, E. T., Pitot, H. C., & Markovic, S. N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.8043 · Cited by 35
FAMMM Syndrome: Pathogenesis and Management
Czajkowski, R., Placek, W. J., Drewa, G., Czajkowska, A., & Uchańska, G. (2004) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2004.30088.x · Cited by 32
Goding, C. R., & Meyskens, F. L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2648 · Cited by 24
p53 plays a central role in UVA and UVB induced cell damage and apoptosis in melanoma cells
Zhang, H. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.12.021 · Cited by 19
Czajkowski, R., Placek, W. J., Drewa, G., Czajkowska, A., & Uchańska, G. (2004) · Dermatologic Surgery · doi:10.1097/00042728-200402002-00010 · Cited by 3
Cited by
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005
Guo, J., Si, L., Kong, Y., Flaherty, K. T., Xu, X., Zhu, Y., Corless, C. L., Li, L., Li, H., Sheng, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9275 · Cited by 688
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Beadling, C., Jacobson-Dunlop, E., Hodi, F. S., Le, C., Warrick, A., Patterson, J., Town, A., Harlow, A., Cruz, F., Azar, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0575 · Cited by 646
Hodi, F. S., Corless, C. L., Giobbie-Hurder, A., Fletcher, J. A., Zhu, M., Marino-Enriquez, A., Friedlander, P., Gonzalez, R., Weber, J. S., Gajewski, T. F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7836 · Cited by 608
Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7636 · Cited by 548
Metadata
- Authors
- Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-04-20
- Volume
- 25
- Issue
- 12
- Pages
- 1606-1620
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2018789635
- Cited by
- 252
- References
- 157
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.